Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer

Overview

Journal Mar Drugs

Publisher MDPI

Specialties Biology
Pharmacology

Date 2017 Sep 21

PMID 28926939

Citations 17

Authors

Fatma H Al-Awadhi

Lilibeth A Salvador

Brian K Law

Valerie J Paul

Hendrik Luesch

Affiliations

Soon will be listed here.

Abstract

Kempopeptin C, a novel chlorinated analogue of kempopeptin B, was discovered from a marine cyanobacterium collected from Kemp Channel in Florida. The structure was elucidated using NMR spectroscopy and mass spectrometry (MS). The presence of the basic Lys residue adjacent to the -terminus of the 3-amino-6-hydroxy-2-piperidone (Ahp) moiety contributed to its selectivity towards trypsin and related proteases. The antiproteolytic activity of kempopeptin C was evaluated against trypsin, plasmin and matriptase and found to inhibit these enzymes with IC values of 0.19, 0.36 and 0.28 μM, respectively. Due to the significance of these proteases in cancer progression and metastasis, as well as their functional redundancy with respect to targeting overlapping substrates, we examined the effect of kempopeptin C on the downstream cellular substrates of matriptase: CDCP1 and desmoglein-2 (Dsg-2). Kempopeptin C was shown to inhibit the cleavage of both substrates in vitro. Additionally, kempopeptin C reduced the cleavage of CDCP1 in MDA-MB-231 cells up to 10 µM. The functional relevance of targeting matriptase and related proteases was investigated by assessing the effect of kempopeptin C on the migration of breast cancer cells. Kempopeptin C inhibited the migration of the invasive MDA-MB-231 cells by 37 and 60% at 10 and 20 µM, respectively.

Citing Articles

Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.

Afkhami H, Yarahmadi A, Bostani S, Yarian N, Haddad M, Lesani S Discov Oncol. 2024; 15(1):818.

PMID: 39707033 PMC: 11662135. DOI: 10.1007/s12672-024-01590-0.

Natural Compounds as Protease Inhibitors in Therapeutic Focus on Cancer Therapy.

Kakali B Anticancer Agents Med Chem. 2024; 24(16):1167-1181.

PMID: 38988167 DOI: 10.2174/0118715206303964240708095110.

Desmoglein-2 as a cancer modulator: friend or foe?.

Myo Min K, Ffrench C, McClure B, Ortiz M, Dorward E, Samuel M Front Oncol. 2024; 13:1327478.

PMID: 38188287 PMC: 10766750. DOI: 10.3389/fonc.2023.1327478.

Naturally Occurring Organohalogen Compounds-A Comprehensive Review.

Gribble G Prog Chem Org Nat Prod. 2023; 121:1-546.

PMID: 37488466 DOI: 10.1007/978-3-031-26629-4_1.

Marine Organisms as a Prolific Source of Bioactive Depsipeptides.

Zeng M, Tao J, Xu S, Bai X, Zhang H Mar Drugs. 2023; 21(2).

PMID: 36827161 PMC: 9966715. DOI: 10.3390/md21020120.

References

Lee S, Dickson R, Lin C . Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 2000; 275(47):36720-5. DOI: 10.1074/jbc.M007802200. View

Linington R, Edwards D, Shuman C, McPhail K, Matainaho T, Gerwick W . Symplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine Cyanobacterium Symploca sp. J Nat Prod. 2008; 71(1):22-7. PMC: 2832912. DOI: 10.1021/np070280x. View

Steeg P . Targeting metastasis. Nat Rev Cancer. 2016; 16(4):201-18. PMC: 7055530. DOI: 10.1038/nrc.2016.25. View

Peitsch W, Doerflinger Y, Fischer-Colbrie R, Huck V, Bauer A, Utikal J . Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells. PLoS One. 2014; 9(2):e89491. PMC: 3928442. DOI: 10.1371/journal.pone.0089491. View

Gesner-Apter S, Carmeli S . Protease inhibitors from a water bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod. 2009; 72(8):1429-36. DOI: 10.1021/np900340t. View

List K . Matriptase: a culprit in cancer?. Future Oncol. 2009; 5(1):97-104. DOI: 10.2217/14796694.5.1.97. View

Brennan D, Mahoney M . Increased expression of Dsg2 in malignant skin carcinomas: A tissue-microarray based study. Cell Adh Migr. 2009; 3(2):148-54. PMC: 2679873. DOI: 10.4161/cam.3.2.7539. View

Law M, Corsino P, Jahn S, Davis B, Chen S, Patel B . Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene. 2012; 32(10):1316-29. PMC: 3773700. DOI: 10.1038/onc.2012.138. View

Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M . Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 2008; 100(3):429-33. PMC: 11158370. DOI: 10.1111/j.1349-7006.2008.01066.x. View

10.

Li P, Jiang S, Lee S, Lin C, Johnson M, Dickson R . Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. J Med Chem. 2007; 50(24):5976-83. DOI: 10.1021/jm0704898. View

11.

Kwan J, Taori K, Paul V, Luesch H . Lyngbyastatins 8-10, elastase inhibitors with cyclic depsipeptide scaffolds isolated from the marine cyanobacterium Lyngbya semiplena. Mar Drugs. 2010; 7(4):528-38. PMC: 2810234. DOI: 10.3390/md7040528. View

12.

Netzel-Arnett S, Hooper J, Szabo R, Madison E, Quigley J, Bugge T . Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003; 22(2-3):237-58. DOI: 10.1023/a:1023003616848. View

13.

Buhring H, Kuci S, Conze T, Rathke G, Bartolovic K, Grunebach F . CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells. 2004; 22(3):334-43. DOI: 10.1634/stemcells.22-3-334. View

14.

Bhatt A, Erdjument-Bromage H, Tempst P, Craik C, Moasser M . Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005; 24(34):5333-43. PMC: 3023961. DOI: 10.1038/sj.onc.1208582. View

15.

Green K, Gaudry C . Are desmosomes more than tethers for intermediate filaments?. Nat Rev Mol Cell Biol. 2001; 1(3):208-16. DOI: 10.1038/35043032. View

16.

Uhland K . Matriptase and its putative role in cancer. Cell Mol Life Sci. 2006; 63(24):2968-78. PMC: 11136049. DOI: 10.1007/s00018-006-6298-x. View

17.

Farady C, Sun J, Darragh M, Miller S, Craik C . The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J Mol Biol. 2007; 369(4):1041-51. PMC: 2041882. DOI: 10.1016/j.jmb.2007.03.078. View

18.

Ormanns S, Altendorf-Hofmann A, Jackstadt R, Horst D, Assmann G, Zhao Y . Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. Br J Cancer. 2015; 113(10):1460-6. PMC: 4815888. DOI: 10.1038/bjc.2015.362. View

19.

Ramani V, Hennings L, Haun R . Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer. 2008; 8:373. PMC: 2628383. DOI: 10.1186/1471-2407-8-373. View

20.

Ustach C, Huang W, Conley-LaComb M, Lin C, Che M, Abrams J . A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res. 2010; 70(23):9631-40. PMC: 3058856. DOI: 10.1158/0008-5472.CAN-10-0511. View